litlas
ログインアカウント作成

David A. D’Alessio

1987–2025 年に発表

126
論文数
29,911
被引用数
92
h 指数
125
i10 指数

被引用数

David A. D’Alessio の年別被引用数1978 年: 被引用 1 件1984 年: 被引用 1 件1987 年: 被引用 1 件1988 年: 被引用 4 件1989 年: 被引用 3 件1990 年: 被引用 9 件1991 年: 被引用 9 件1992 年: 被引用 15 件1993 年: 被引用 7 件1994 年: 被引用 8 件1995 年: 被引用 9 件1996 年: 被引用 20 件1997 年: 被引用 14 件1998 年: 被引用 23 件1999 年: 被引用 27 件2000 年: 被引用 18 件2001 年: 被引用 35 件2002 年: 被引用 49 件2003 年: 被引用 75 件2004 年: 被引用 108 件2005 年: 被引用 108 件2006 年: 被引用 129 件2007 年: 被引用 146 件2008 年: 被引用 169 件2009 年: 被引用 190 件2010 年: 被引用 178 件2011 年: 被引用 220 件2012 年: 被引用 191 件2013 年: 被引用 259 件2014 年: 被引用 213 件2015 年: 被引用 250 件2016 年: 被引用 251 件2017 年: 被引用 201 件2018 年: 被引用 230 件2019 年: 被引用 1,041 件2020 年: 被引用 1,500 件2021 年: 被引用 1,444 件2022 年: 被引用 1,074 件2023 年: 被引用 805 件2024 年: 被引用 1,371 件2025 年: 被引用 778 件2026 年: 被引用 37 件1979〜1983 年は被引用が無いため表示していません1985〜1986 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,222 件、この内訳の 24.4%イギリス: 引用元論文 1,060 件、この内訳の 8%中国: 引用元論文 916 件、この内訳の 6.9%ドイツ: 引用元論文 632 件、この内訳の 4.8%イタリア: 引用元論文 622 件、この内訳の 4.7%カナダ: 引用元論文 619 件、この内訳の 4.7%デンマーク: 引用元論文 586 件、この内訳の 4.5%オーストラリア: 引用元論文 425 件、この内訳の 3.2%スウェーデン: 引用元論文 344 件、この内訳の 2.6%フランス: 引用元論文 334 件、この内訳の 2.5%スペイン: 引用元論文 333 件、この内訳の 2.5%日本: 引用元論文 326 件、この内訳の 2.5%
0%24.4%その他 28.7%

機関

分野

  • Medicine70%
  • Neuroscience13%
  • Biochemistry, Genetics and Molecular Biology10.1%
  • Nursing2.2%
  • Psychology1.1%
  • Agricultural and Biological Sciences0.7%
  • その他2.9%

トピック

  • Diabetes Treatment and Management13.5%
  • Pancreatic function and diabetes6.7%
  • Regulation of Appetite and Obesity5.7%
  • Diet and metabolism studies5.5%
  • Diabetes Management and Research4.1%
  • Metabolism, Diabetes, and Cancer3.9%
  • その他60.6%

共著者

全論文

検索で開く
  1. Glucagon-like peptide 1 (GLP-1)

    著者: Timo D. Müller, Brian Finan, Stephen R. Bloom, David A. D’Alessio, Daniel J. Drucker, Peter R. Flatt, Andreas Fritsche, Fiona M. Gribble, Harvey J. Grill, Joel F. Habener, Jens J. Holst, Wolfgang Langhans, Juris J. Meier, Michael A. Nauck, Diego Pérez–Tilve, Alessandro Pocai, Frank Reimann, Darleen A. Sandoval, Thue W. Schwartz, Randy J. Seeley, Kerstin Stemmer, Mads Tang‐Christensen, Stephen C. Woods, Richard D. DiMarchi, M. Tschöp - Molecular Metabolism 2019 被引用: 1,738

  2. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

    著者: Tamer Coşkun, Kyle W. Sloop, Corina Loghin, Jorge Alsina‐Fernandez, Shweta Urva, Krister Bokvist, Xuewei Cui, Daniel A. Briere, Over Cabrera, William C. Roell, Uma Kuchibhotla, Julie S. Moyers, Charles Benson, Ruth E. Gimeno, David A. D’Alessio, Axel Haupt - Molecular Metabolism 2018 被引用: 822

  3. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

    著者: Melanie J. Davies, David A. D’Alessio, Judith Fradkin, Walter N. Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Απόστολος Τσάπας, Deborah J. Wexler, John B. Buse - Diabetes Care 2018 被引用: 3,513

  4. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

    著者: Francis S. Willard, Jonathan D. Douros, M Gabe, Aaron D. Showalter, David B. Wainscott, Todd M. Suter, Megan E. Capozzi, Wijnand J. C. van der Velden, Cynthia Stutsman, Guemalli R. Cardona, Shweta Urva, Paul J. Emmerson, Jens J. Holst, David A. D’Alessio, Matthew P. Coghlan, Mette M. Rosenkilde, Jonathan E. Campbell, Kyle W. Sloop - JCI Insight 2020 被引用: 487

  5. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

    著者: Stephen J. Nicholls, Deepak L. Bhatt, John B. Buse, Stefano Del Prato, Steven E. Kahn, A. Michael Lincoff, Darren K. McGuire, Michael A. Nauck, Steven E. Nissen, Naveed Sattar, Bernard Zinman, Sophia Zoungas, Jan Basile, Amy Bartee, Debra L. Miller, Hiroshi Nishiyama, Imre Pávó, Govinda J. Weerakkody, Russell J. Wiese, David A. D’Alessio - American Heart Journal 2023 被引用: 222

  6. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

    著者: John B. Buse, Deborah J. Wexler, Απόστολος Τσάπας, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A. D’Alessio, Melanie J. Davies - Diabetes Care 2019 被引用: 1,189

  7. Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease

    著者: Darleen A. Sandoval, David A. D’Alessio - Physiological Reviews 2015 被引用: 491

  8. Ghrelin

    著者: Timo D. Müller, Rubén Nogueiras, Mark L. Andermann, Zane B. Andrews, Stefan D. Anker, Jesús Argente, Rachel L. Batterham, S.C. Benoit, C. Y. Bowers, Fabio Broglio, Felipe F. Casanueva, David A. D’Alessio, Inge Depoortere, Allan Geliebter, Ezio Ghigo, Philip A. Cole, Michael A. Cowley, D. E. Cummings, Alain Dagher, Sabrina Diano, Suzanne L. Dickson, Carlos Diéguez, Riccarda Granata, Harvey J. Grill, Kelly Grove, Kirk M. Habegger, Kristy M. Heppner, Mark L. Heiman, Laura M. Holsen, Birgitte Holst, Akio Inui, J-O Jansson, Henriette Kirchner, Márta Korbonits, Blandine Laferrère, C.W. LeRoux, Miguel López, Sophie Morin, Michiko Nakazato, Ralf Nass, Diego Pérez–Tilve, Paul T. Pfluger, Thue W. Schwartz, Randy J. Seeley, Mark W. Sleeman, Yuxiang Sun, Lori Sussel, Jenny Tong, Michael O. Thorner, A. J. van der Lely, L. H. T. Van der Ploeg, Jeffrey M. Zigman, Masayasu Kojima, Kenji Kangawa, R G Smith, Tamás L. Horváth, M. Tschöp - Molecular Metabolism 2015 被引用: 1,008

  9. Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect

    著者: Stephanie Sisley, Ruth Gutiérrez‐Aguilar, Michael M. Scott, David A. D’Alessio, Darleen A. Sandoval, Randy J. Seeley - Journal of Clinical Investigation 2014 被引用: 399

  10. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

    著者: Shweta Urva, Tamer Coşkun, Mei Teng Loh, Yu Du, Melissa K. Thomas, Sirel Gurbuz, Axel Haupt, Charles Benson, Martha Hernandez‐Illas, David A. D’Alessio, Zvonko Miličević - The Lancet 2022 被引用: 189

  11. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets

    著者: Kimberley El, Jonathan D. Douros, Francis S. Willard, Aaron Novikoff, Ashot Sargsyan, Diego Pérez–Tilve, David B. Wainscott, Bin Yang, A. Y. Chen, Donald Wothe, Callum Coupland, Mattias H. Tschöp, Brian Finan, David A. D’Alessio, Kyle W. Sloop, Timo D. Müller, Jonathan E. Campbell - Nature Metabolism 2023 被引用: 112

  12. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications

    著者: Jonathan E. Campbell, Timo D. Müller, Brian Finan, Richard D. DiMarchi, Matthias H. Tschöp, David A. D’Alessio - Cell Metabolism 2023 被引用: 128

  13. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

    著者: Melanie J. Davies, David A. D’Alessio, Judith Fradkin, Walter N. Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Απόστολος Τσάπας, Deborah J. Wexler, John B. Buse - Diabetologia 2018 被引用: 1,466

  14. β Cell tone is defined by proglucagon peptides through cAMP signaling

    著者: Megan E. Capozzi, Berit Svendsen, Sara E. Encisco, Sophie L. Lewandowski, Mackenzie D. Martin, Haopeng Lin, Justin L. Jaffe, Reilly W. Coch, Jonathan M. Haldeman, Patrick E. MacDonald, Matthew J. Merrins, David A. D’Alessio, Jonathan E. Campbell - JCI Insight 2019 被引用: 256

  15. GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells

    著者: Kimberley El, Sarah M. Gray, Megan E. Capozzi, Emily R. Knuth, Enyou Jin, Berit Svendsen, Alexis L. Clifford, Jennifer Brown, Sara E. Encisco, Bryanna M. Chazotte, Kyle W. Sloop, Derek J. Nunez, Matthew J. Merrins, David A. D’Alessio, Jonathan E. Campbell - Science Advances 2021 被引用: 125

  16. GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials

    著者: Ishani Kapoor, Swara M. Sarvepalli, David A. D’Alessio, Dilraj S. Grewal, Majda Hadziahmetovic - Survey of Ophthalmology 2023 被引用: 67

  17. Glucagon lowers glycemia when β cells are active

    著者: Megan E. Capozzi, Jacob B. Wait, Jepchumba Koech, Andrew N. Gordon, Reilly W. Coch, Berit Svendsen, Brian Finan, David A. D’Alessio, Jonathan E. Campbell - JCI Insight 2019 被引用: 168

  18. Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans

    著者: Juraj Koška, Michelle Sands, Camelia Burciu, Karen D’Souza, Kalyani Raravikar, James Liu, Seth Truran, Daniel Franco, Eric A. Schwartz, Dawn C. Schwenke, David A. D’Alessio, Raymond Q. Migrino, Peter D. Reaven - Diabetes 2015 被引用: 166

  19. Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions

    著者: Kirk M. Habegger, Kerstin Stemmer, Christine C. Cheng, Timo D. Müller, Kristy M. Heppner, Nickki Ottaway, Jenna Holland, Jazzminn Hembree, David L. Smiley, Vasily M. Gelfanov, Radha Krishna, Ayman M. Arafat, Anish Konkar, Sara Belli, Martin Kapps, Stephen C. Woods, Susanna M. Hofmann, David A. D’Alessio, Paul T. Pfluger, Diego Pérez–Tilve, Randy J. Seeley, Morichika Konishi, Nobuyujki Itoh, Alexei Kharitonenkov, Joachim Spranger, Richard D. DiMarchi, Matthias H. Tschöp - Diabetes 2013 被引用: 244

  20. Characterization of genetic variants of GIPR reveals a contribution of β-arrestin to metabolic phenotypes

    著者: Hüsün Sheyma Kizilkaya, Kimmie V. Sørensen, Jakob Sture Madsen, Peter Lindquist, Jonathan D. Douros, Jette Bork‐Jensen, Alessandro Berghella, P. Gerlach, Lærke S. Gasbjerg, Jacek Mokrosiński, Stephanie A. Mowery, Patrick J. Knerr, Brian Finan, Jonathan E. Campbell, David A. D’Alessio, Diego Pérez–Tilve, Felix Faas, Signe Mathiasen, Jørgen Rungby, Henrik Toft Sørensen, Allan Vaag, Jens Steen Nielsen, Jens‐Christian Holm, Jeannet Lauenborg, Peter Damm, Oluf Pedersen, Allan Linneberg, Bolette Hartmann, Jens J. Holst, Torben Hansen, Shane C. Wright, Volker M. Lauschke, Niels Grarup, Alexander S. Hauser, Mette M. Rosenkilde - Nature Metabolism 2024 被引用: 42

  21. The past, present, and future physiology and pharmacology of glucagon

    著者: Megan E. Capozzi, David A. D’Alessio, Jonathan E. Campbell - Cell Metabolism 2022 被引用: 102

  22. The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice

    著者: Adam P. Chambers, Joyce Sorrell, April Haller, Karen J. Roelofs, Chelsea R. Hutch, Ki‐Suk Kim, Ruth Gutiérrez‐Aguilar, Bailing Li, Daniel J. Drucker, David A. D’Alessio, Randy J. Seeley, Darleen A. Sandoval - Cell Metabolism 2017 被引用: 242

  23. GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue

    著者: Jonathan E. Campbell, Jacqueline L. Beaudry, Berit Svendsen, Laurie L. Baggio, Andrew N. Gordon, John R. Ussher, Chi Kin Wong, Fiona M. Gribble, David A. D’Alessio, Frank Reimann, Daniel J. Drucker - Diabetes 2022 被引用: 62

  24. GLP-1 and energy balance: an integrated model of short-term and long-term control

    著者: Jason G. Barrera, Darleen A. Sandoval, David A. D’Alessio, Randy J. Seeley - Nature Reviews Endocrinology 2011 被引用: 218